Patients with higher levels of vitamin D are less likely to die from skin cancer

NewsGuard 100/100 Score

New research shows higher levels of vitamin D may help improve survival for both bowel and skin cancer patients.

The results of two studies published in the British Journal of Cancer and Journal of Clinical Oncology found people with higher levels of vitamin D - at the time they were diagnosed - were more likely to survive.

In the first study researchers from the Dana-Farber Cancer Institute, Boston followed 1017 bowel cancer patients for around nine years.

Using information about UV-B and sunlight exposure, skin type, body-mass index, and vitamin D intake from food and supplements they estimated the amount of vitamin D in patients' blood at the time of diagnosis.

The results showed that those with higher vitamin D scores after being diagnosed with cancer were 50 per cent less likely to die from the disease - compared to those with lower vitamin D scores.

Professor Kimmie Ng, study author, said: "Our study shows that levels of vitamin D after colorectal cancer diagnosis may be important for survival. We are now planning further research in patients with bowel cancer to see if vitamin D has the same effect, and to investigate how vitamin D works with molecular and genetic pathways in the cell to fight cancer."

The second study - funded by Cancer Research UK and the National Institutes of Health - found that malignant melanoma patients** with the lowest levels of vitamin D in their blood at the time they were diagnosed were 30 per cent more likely to relapse from the disease than those with the highest levels.

The researchers from Leeds also found that patients who have higher levels of vitamin D at diagnosis have thinner tumours at diagnosis.

Professor Julia Newton Bishop, study author at the Leeds Institute of Molecular Medicine, said: "It's common for the general public to have low levels of vitamin D in many countries. Melanoma patients tend to avoid the sun as sunburn is known to increase the risk of melanoma. We use sunshine to make vitamin D in the skin, so melanoma patients' levels of vitamin D may be especially low.

"Our results suggest that melanoma patients may need to get vitamin D by eating fatty fish or by taking supplements to ensure they have normal levels. But we are continuing to carry out research to find out the optimum level of vitamin D. There's some evidence from other health studies that high levels of vitamin D are also harmful - so we should aim for a normal level rather than a very high one."

Sara Hiom, director of health information at Cancer Research UK, said: "Both these studies support the theory that higher levels of vitamin D can improve the chance of surviving cancer. The key is to get the right balance between the amount of time spent in the sun and the levels of vitamin D needed for good health.

"But protection from burning in the sun is still vital. Cancer Research UK's SunSmart campaign advises that people with lots of moles, red hair fair skin and a family history of the disease should take extra care in the sun as they are more at risk of the most dangerous form of skin cancer Anyone who is worried about changes in their moles should go to their GP."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis